Enanta Pharmaceuticals
ENTA
195 hedge funds and large institutions have $1.7B invested in Enanta Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 73 increasing their positions, 59 reducing their positions, and 15 closing their positions.
93% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 15
43% more capital invested
Capital invested by funds: $1.19B → $1.7B (+$508M)
24% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 59
7% more funds holding
Funds holding: 183 → 195 (+12)
4.86% more ownership
Funds ownership: 86.75% → 91.61% (+4.9%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
32% less call options, than puts
Call options by funds: $5.14M | Put options by funds: $7.51M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$26.5M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
+$23.1M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$21.5M |
| 4 |
O
OrbiMed
New York
|
+$20.9M |
| 5 |
MWNA
Marshall Wace North America
New York
|
+$18.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$13.6M |
| 2 |
AC
Armistice Capital
New York
|
-$11.5M |
| 3 |
Morgan Stanley
New York
|
-$10.3M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$10.2M |
| 5 |
Goldman Sachs
New York
|
-$6.74M |
ENTA Hedge Fund Activity: Q1 2019 in Review
195 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q1 2019, worth a combined $1.7B — up 43% from $1.19B a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new ENTA positions and 15 closed out — a net gain of 14 holders — while 73 added to existing stakes and 59 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $26.5M. The largest seller was Renaissance Technologies, cutting an estimated $13.6M.
- 195 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q1 2019, up from 183 in Q4 2018.
- Funds reported $1.7B of Enanta Pharmaceuticals stock for Q1 2019, up 43% quarter-over-quarter.
- 29 funds opened new Enanta Pharmaceuticals positions in Q1 2019 and 15 closed out, a net change of +14 holders.
- The largest Enanta Pharmaceuticals buyer in Q1 2019 was T. Rowe Price Associates, an estimated $26.5M added.
- The largest Enanta Pharmaceuticals seller in Q1 2019 was Renaissance Technologies, an estimated $13.6M sold.
Based on aggregated 13F filings for Q1 2019.